Log in

NASDAQ:RDNTRadNet Stock Price, Forecast & News

$15.40
+0.38 (+2.53 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.75
Now: $15.40
$15.43
50-Day Range
$14.54
MA: $16.41
$18.60
52-Week Range
$5.81
Now: $15.40
$23.45
Volume320,500 shs
Average Volume436,274 shs
Market Capitalization$780.70 million
P/E Ratio385.10
Dividend YieldN/A
Beta1.69
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Read More
RadNet logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.15 billion
Cash Flow$3.39 per share
Book Value$4.63 per share

Profitability

Net Income$14.76 million

Miscellaneous

Employees8,498
Market Cap$780.70 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

RadNet (NASDAQ:RDNT) Frequently Asked Questions

How has RadNet's stock been impacted by COVID-19 (Coronavirus)?

RadNet's stock was trading at $17.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDNT stock has decreased by 10.6% and is now trading at $15.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of RadNet?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for RadNet.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for RadNet.

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) issued its quarterly earnings data on Monday, May, 11th. The medical research company reported ($0.33) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.16. The medical research company earned $281.60 million during the quarter, compared to analyst estimates of $242.09 million. RadNet had a net margin of 0.18% and a return on equity of 1.56%. The firm's quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.08) earnings per share. View RadNet's earnings history.

What price target have analysts set for RDNT?

1 analysts have issued 1 year price objectives for RadNet's shares. Their forecasts range from $23.00 to $23.00. On average, they expect RadNet's stock price to reach $23.00 in the next year. This suggests a possible upside of 49.4% from the stock's current price. View analysts' price targets for RadNet.

Has RadNet been receiving favorable news coverage?

Headlines about RDNT stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. RadNet earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about RadNet.

Are investors shorting RadNet?

RadNet saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 943,800 shares, a decline of 12.6% from the June 15th total of 1,080,000 shares. Based on an average daily volume of 492,700 shares, the days-to-cover ratio is currently 1.9 days. Approximately 2.2% of the company's shares are short sold. View RadNet's Current Options Chain.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a number of institutional and retail investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (1.98%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View institutional ownership trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co.. Company insiders that have sold RadNet company stock in the last year include John V Crues, Mark Stolper, Michael L Md Sherman, and Norman R Hames. View insider buying and selling activity for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $15.40.

How big of a company is RadNet?

RadNet has a market capitalization of $780.70 million and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 8,498 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.